Literature DB >> 8984033

Attenuated GLP-1 secretion in obesity: cause or consequence?

L R Ranganath1, J M Beety, L M Morgan, J W Wright, R Howland, V Marks.   

Abstract

BACKGROUND: Hypersecretion of insulinotropic factors such as glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(7-36)amide (GLP-1) have been postulated to account for the hyperinsulinaemia of obesity. AIMS: To examine the role of GLP-1 and GIP in obese women and matched controls.
SUBJECTS: Six lean and six obese women subjects matched for age.
METHODS: The gut hormone, plasma glucose, and serum triglyceride responses were studied over 180 minutes after oral carbohydrate and fat meals. Heparin (10,000 units) was given intravenously at 120 minutes.
RESULTS: There was pronounced attenuation of plasma GLP-1 secretion to oral carbohydrate in the obese compared with lean subjects but no such difference in response to oral fat load. There were no differences in the plasma GIP responses to carbohydrate or fat feeding. There was an apparent fall in plasma GLP-1 values in all subjects after administration of heparin.
CONCLUSION: Postprandial GLP-1 secretion in response to oral carbohydrate is considerably attenuated in obese subjects. The cause of this attenuation of GLP-1 secretion is not known although we suggest that both this fall and the overall reduction in GLP-1 values in obese subjects may be related to an increase in plasma non-esterified fatty acids.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8984033      PMCID: PMC1383202          DOI: 10.1136/gut.38.6.916

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE.

Authors:  N MCINTYRE; C D HOLDSWORTH; D S TURNER
Journal:  Lancet       Date:  1964-07-04       Impact factor: 79.321

2.  The enteroinsular axis revisited. A novel role for an incretin.

Authors:  J W Ensinck; D A D'Alessio
Journal:  N Engl J Med       Date:  1992-05-14       Impact factor: 91.245

3.  Plasma free fatty acid turnover rate in obesity.

Authors:  P Björntorp; H Bergman; E Varnauskas
Journal:  Acta Med Scand       Date:  1969-04

4.  Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut.

Authors:  J J Holst; C Orskov; O V Nielsen; T W Schwartz
Journal:  FEBS Lett       Date:  1987-01-26       Impact factor: 4.124

5.  Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable.

Authors:  C Orskov; A Wettergren; J J Holst
Journal:  Diabetes       Date:  1993-05       Impact factor: 9.461

6.  Exon duplication and divergence in the human preproglucagon gene.

Authors:  G I Bell; R Sanchez-Pescador; P J Laybourn; R C Najarian
Journal:  Nature       Date:  1983 Jul 28-Aug 3       Impact factor: 49.962

7.  Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.

Authors:  N Fukase; M Igarashi; H Takahashi; H Manaka; K Yamatani; M Daimon; M Tominaga; H Sasaki
Journal:  Diabet Med       Date:  1993 Jan-Feb       Impact factor: 4.359

8.  Radioimmunoassay of gastric inhibitory polypeptide.

Authors:  L M Morgan; B A Morris; V Marks
Journal:  Ann Clin Biochem       Date:  1978-05       Impact factor: 2.057

9.  Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

Authors:  R M Elliott; L M Morgan; J A Tredger; S Deacon; J Wright; V Marks
Journal:  J Endocrinol       Date:  1993-07       Impact factor: 4.286

10.  Glucagon-like peptide-1 7-36: a physiological incretin in man.

Authors:  B Kreymann; G Williams; M A Ghatei; S R Bloom
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

View more
  83 in total

Review 1.  Promising new approaches to the management of obesity.

Authors:  I L Mertens; L F Van Gaal
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

2.  Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents.

Authors:  Hui Chen; David Simar; Katherine Pegg; Sonia Saad; Clovis Palmer; Margaret J Morris
Journal:  Diabetologia       Date:  2013-12-14       Impact factor: 10.122

Review 3.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Authors:  M A Nauck; I Vardarli; C F Deacon; J J Holst; J J Meier
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

Review 4.  Potential use of exenatide for the treatment of obesity.

Authors:  Franco Folli; Rodolfo Guardado Mendoza
Journal:  Expert Opin Investig Drugs       Date:  2011-10-24       Impact factor: 6.206

5.  Ability of GLP-1 to decrease food intake is dependent on nutritional status.

Authors:  Charlotte C Ronveaux; Guillaume de Lartigue; Helen E Raybould
Journal:  Physiol Behav       Date:  2014-06-21

6.  Nutrient-specific feeding and endocrine effects of jejunal infusions in obese animals.

Authors:  Megan J Dailey; Alexander A Moghadam; Timothy H Moran
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-01-22       Impact factor: 3.619

7.  Acute effect of walking on energy intake in overweight/obese women.

Authors:  Jessica L Unick; Amy D Otto; Bret H Goodpaster; Diane L Helsel; Christine A Pellegrini; John M Jakicic
Journal:  Appetite       Date:  2010-07-30       Impact factor: 3.868

8.  Circulating ghrelin and GLP-1 are not affected by habitual diet.

Authors:  Amy C Ellis; Paula Chandler-Laney; Krista Casazza; Laura Lee Goree; Gerald McGwin; Barbara A Gower
Journal:  Regul Pept       Date:  2012-02-28

Review 9.  Effect of inulin-type fructans on blood lipid profile and glucose level: a systematic review and meta-analysis of randomized controlled trials.

Authors:  F Liu; M Prabhakar; J Ju; H Long; H-W Zhou
Journal:  Eur J Clin Nutr       Date:  2016-09-14       Impact factor: 4.016

Review 10.  The environment within: how gut microbiota may influence metabolism and body composition.

Authors:  A Vrieze; F Holleman; E G Zoetendal; W M de Vos; J B L Hoekstra; M Nieuwdorp
Journal:  Diabetologia       Date:  2010-01-26       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.